GR2102

GR2102 is a recombinant all-human monoclonal antibody developed for the prevention of respiratory syncytial virus (RSV) infection. It specifically targets and binds to the Fusion glycoprotein F of respiratory syncytial virus on the surface of RSV, thereby blocking viral entry into host cells and preventing infection. The drug is being independently developed by Genrix Biopharmaceutical (also referred to as Zhixiang Jintai or Zhixiang (Shanghai) Medical Technology), with clinical trials currently underway in China. Its primary indication is for RSV infections, and it is administered via injection. As of now, there are no approved indications or known adverse events reported for this drug[1][2][3][4][5].